Filter Results:
(447)
Show Results For
- All HBS Web
(636)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
Show Results For
- All HBS Web
(636)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
Sort by
- 16 Jun 2003
- Research & Ideas
Surveying the VC Landscape
public within five to seven years of its initial financing, will be able to pursue research that will not have a payoff for fifteen, twenty, or even more years in the future. (But it's not impossible—after all, venture capital has played a key role in the financing of... View Details
- 13 Jun 2005
- Research & Ideas
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology
in many cases, perform identical procedures in two or more hospitals during the course of a given week. We have found that this movement has negative effects on the degree to which surgeons are able to leverage their prior experience to improve future performance. We... View Details
- July 2013
- Case
Novozymes: Establishing the Cellulosic Ethanol Value Chain
By: Willy Shih and Sen Chai
As the world's largest producer of industrial enzymes, Novozymes had invested heavily for many years to bio-engineer enzymes that could break down cellulose into fermentable sugar. In 2010, the company had launched what it thought would become a breakthrough product... View Details
Keywords: System Complexity; Industrial Enzymes; Ethanol; Collulosic Ethanol; Fermentation; Genomics; Genetic Engineering; Value Chain; Assembling Value Chain; Energy Sources; Renewable Energy; Collaborative Innovation and Invention; Innovation and Management; Innovation Strategy; Technological Innovation; Management; Growth and Development Strategy; Industry Growth; Production; Research; Research and Development; Science; Genetics; Natural Environment; Environmental Sustainability; Science-Based Business; Business Strategy; Commercialization; Vertical Integration; Agriculture and Agribusiness Industry; Biotechnology Industry; Energy Industry; Denmark; United States
Shih, Willy, and Sen Chai. "Novozymes: Establishing the Cellulosic Ethanol Value Chain." Harvard Business School Case 614-001, July 2013.
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- May 2015
- Case
Transforming Alkermes into a Global Biopharmaceutical Company
By: C. Fritz Foley and Nicholas Haas
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
Keywords: Financing; Debt; Merger; CFO; Financial Management; Biotechnology Industry; Biotechnology Industry; United States; Europe
Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057. View Details
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Biotechnology Industry; Biotechnology Industry; Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Biotechnology Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Biotechnology Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- September 2008
- Teaching Note
Chi Mei Optoelectronics (TN)
By: Willy C. Shih
Teaching Note for [608-123]. View Details
- September 2007 (Revised May 2009)
- Case
Syndexa and Technology Transfer at Harvard University
By: Richard G. Hamermesh and David Kiron
Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the... View Details
Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Hamermesh, Richard G., and David Kiron. "Syndexa and Technology Transfer at Harvard University." Harvard Business School Case 808-073, September 2007. (Revised May 2009.)
- November 2006 (Revised March 2008)
- Case
The Harvard Stem Cell Institute
Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how... View Details
Keywords: Talent and Talent Management; Higher Education; Entrepreneurship; Collaborative Innovation and Invention; Intellectual Property; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry; Massachusetts
Sahlman, William A. "The Harvard Stem Cell Institute." Harvard Business School Case 807-096, November 2006. (Revised March 2008.)
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well... View Details
Keywords: Valuation; Price; Investment Return; Capital; Value; Revenue; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; Massachusetts
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)
- March 2005 (Revised August 2005)
- Case
Procurement at Betapharm Corp. (A)
Presents a move by Betapharm to centralize procurement and e-sourcing and the many control and incentive issues that arose subsequently. View Details
Keywords: Motivation and Incentives; Governance Controls; Supply Chain Management; Biotechnology Industry; Biotechnology Industry
Kulp, Susan L., and Taylor Randall. "Procurement at Betapharm Corp. (A)." Harvard Business School Case 105-030, March 2005. (Revised August 2005.)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
Keywords: Health Disorders; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- November 1998 (Revised October 1999)
- Case
E.I. du Pont de Nemours and Company (A)
Du Pont's chief executive must decide what steps to take as his company expands from commodity and specialized chemicals into biotechnology. View Details
West, Jonathan. "E.I. du Pont de Nemours and Company (A)." Harvard Business School Case 699-037, November 1998. (Revised October 1999.)
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Biotechnology Industry; Biotechnology Industry; Germany; North America; United States
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne
- 14 Sep 2010
- First Look
First Look: September 14, 2010
involved in the production of clean energy. One of the key bottlenecks threatening innovation in energy production is the inability of VCs to exit their investments at the appropriate time. This hurdle did exist in industries such as View Details
Keywords: Sean Silverthorne